Eagle Pharmaceuticals Insiders
Eagle Pharmaceuticals employs about 134 people. The company is managed by 12 executives with a total tenure of roughly 35 years, averaging almost 2.0 years of service per executive, having 11.17 employees per reported executive. Break down of Eagle Pharmaceuticals' management performance can provide insight into the company performance.
| Scott Tarriff CEO CEO and President Director and Member of Executive Committee |
Eagle |
Eagle Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of 0.0663 % which means that it generated a profit of $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0488 %, meaning that it created $0.0488 on every $100 dollars invested by stockholders. Eagle Pharmaceuticals' management efficiency ratios could be used to measure how well Eagle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Eagle Pharmaceuticals Workforce Comparison
Eagle Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 14,154. Eagle Pharmaceuticals maintains roughly 134 in number of employees contributing less than 1% to equities under Health Care industry.
The company has Profit Margin (PM) of 0.05 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.16 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.16. Eagle Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eagle Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eagle Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Eagle Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Brian Cahill over six months ago Disposition of 735 shares by Brian Cahill of Eagle Pharmaceuticals at 5.13 subject to Rule 16b-3 | ||
Scott Tarriff over a year ago Payment of 2119 shares by Scott Tarriff of Eagle Pharmaceuticals subject to Rule 16b-3 | ||
Scott Tarriff over a year ago Disposition of 3154 shares by Scott Tarriff of Eagle Pharmaceuticals at 6.44 subject to Rule 16b-3 | ||
Scott Tarriff over a year ago Sale by Scott Tarriff of 7802 shares of Eagle Pharmaceuticals | ||
Scott Tarriff over a year ago Sale by Scott Tarriff of 10925 shares of Eagle Pharmaceuticals | ||
Scott Tarriff over a year ago Sale by Scott Tarriff of 9511 shares of Eagle Pharmaceuticals | ||
Scott Tarriff over a year ago Payment of 3113 shares by Scott Tarriff of Eagle Pharmaceuticals subject to Rule 16b-3 |
Eagle Pharmaceuticals Notable Stakeholders
An Eagle Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Eagle Pharmaceuticals often face trade-offs trying to please all of them. Eagle Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Eagle Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Scott Tarriff | CEO and President Director and Member of Executive Committee | Profile | |
| Michael Graves | Independent Director | Profile | |
| Steven Ratoff | Independent Director | Profile | |
| Ryan Debski | General VP | Profile | |
| Debra Hussain | Senior Commercial | Profile | |
| Gaozhong Zhu | Senior Development | Profile | |
| Reiner Nowak | Exec | Profile | |
| John Kimmet | Ex Care | Profile | |
| Daniel OConnor | Chief VP | Profile | |
| Valentin MD | Senior Development | Profile | |
| Brian Cahill | Chief Officer | Profile | |
| Reed McClung | Executive Development | Profile |
Eagle Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Eagle Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Eagle Pharmaceuticals within its industry.Eagle Pharmaceuticals Manpower Efficiency
Return on Eagle Pharmaceuticals Manpower
| Revenue Per Employee | 2.4M | |
| Revenue Per Executive | 26.4M | |
| Net Loss Per Employee | 19.9K | |
| Net Loss Per Executive | 222.2K | |
| Working Capital Per Employee | 579.6K | |
| Working Capital Per Executive | 6.5M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Eagle Pink Sheet
If you are still planning to invest in Eagle Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eagle Pharmaceuticals' history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |